



## Shareholders of Molecular Partners AG approve all Board proposals at the Annual General Meeting

April 16, 2019

**Zurich-Schlieren, April 16, 2019.** At today's Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics\* to treat serious diseases, the shareholders of the company approved all motions proposed by the Board of Directors with a very large majority.

At today's Annual General Meeting of Molecular Partners AG, Bill Burns, Göran Ando, Gwen Fyfe, Steven H. Holtzman, William A. Lee, Petri Vainio and Patrick Amstutz were re-elected as members of the Board of Directors for a term of office until the 2020 Annual General Meeting. Bill Burns was re-elected as Chairman of the Board of Directors. The shareholders also elected the three proposed members of the Nomination and Compensation Committee – Bill Burns, Göran Ando and William A. Lee.

KPMG AG Zurich was re-elected as the Group's statutory auditors for the financial year 2019 and Anwaltskanzlei Keller KLG, Zurich, elected as the independent proxy for a term of office until the 2020 Annual General Meeting.

The Annual General Meeting approved all (binding) motions regarding compensation of the Board of Directors and the Management Board. Further, the shareholders of Molecular Partners AG approved the annual report and the annual financial statements for the financial year 2018, the appropriation of the 2018 results, as well as the compensation report (in a consultative vote). The Board of Directors and the Management Board were granted discharge for the financial year 2018.

### Financial Calendar

- May 9, 2019 – Interim Management Statement Q1 2019
- August 27, 2019 – Publication of Half-year Results 2019 (unaudited)
- October 31, 2019 – Interim Management Statement Q3 2019

<http://investors.molecularpartners.com/financial-calendar-and-events/>

### About the DARPin® Difference

DARPin® therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin® candidates are potent, specific, safe and very versatile. They can engage more than 5 targets at once, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their good safety profile, low immunogenicity and long half-life in the bloodstream and the eye, DARPin® therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology, and is advancing a proprietary pipeline of DARPin® drug candidates in oncology and immuno-oncology. The most advanced global product candidate is abicipar, a molecule currently in phase 3, in partnership with Allergan. Several DARPin® molecules for various ophthalmic indications are also in development. The most advanced DARPin® therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of solid tumors and hematological tumors. MP0274, the second-most advanced DARPin® drug candidate owned by Molecular Partners, has broad anti-HER activity; it inhibits HER1, HER2 and HER3-mediated downstream signaling via Her2, leading to induction of apoptosis. MP0274 is currently in phase 1. The company's lead immuno-oncology product candidate MP0310 is a FAP x 4-1BB multi-DARPin® therapeutic candidate designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). Molecular Partners has closed a collaboration agreement with Amgen for the exclusive clinical development and commercialization of MP0310. MP0310 is expected to enter into the clinic in H2 2019. Molecular Partners is also advancing a growing preclinical and research pipeline in immuno-oncology that features its 'I/O toolbox' and additional development programs. DARPin® is a registered trademark owned by Molecular Partners AG.

### About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: [www.molecularpartners.com](http://www.molecularpartners.com).

### For further details, please contact:

Dr. Patrick Amstutz, CEO  
[patrick.amstutz@molecularpartners.com](mailto:patrick.amstutz@molecularpartners.com)  
Tel: +41 44 755 77 00

Dr. Thomas Schneckenburger, IR & Media  
[thomas.schneckenburger@molecularpartners.com](mailto:thomas.schneckenburger@molecularpartners.com)  
Tel: +41 44 755 5728

Susan A. Noonan, IR USA  
[susan@sanoonan.com](mailto:susan@sanoonan.com)  
Tel: +1 212 966 3650

Lisa Raffensperger, International Media  
[lisa@tenbridgecommunications.com](mailto:lisa@tenbridgecommunications.com)  
Tel: +1 617 903 8783

\*DARPin® is a registered trademark owned by Molecular Partners AG

#### **Disclaimer**

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.